Latest Breaking News On - ஜெநரேஶந் உயிர் - Page 4 : comparemela.com
Portfolio of BB Biotech AG as of December 31, 2020
ifamagazine.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ifamagazine.com Daily Mail and Mail on Sunday newspapers.
DGAP-News: BB BIOTECH AG / Key word(s): Annual Results/Dividend
BB BIOTECH AG: Vaccines leading the way out of the pandemic - increased dividend of CHF 3.60 proposed
22.01.2021 / 07:00
Media release as of January 22, 2021
Portfolio of BB Biotech AG as of December 31, 2020
Vaccines leading the way out of the pandemic - increased dividend of CHF 3.60 proposed
BB Biotech performed well in 2020 in a volatile market environment. The biotech sector made significant strides, leading the effort against the SARS-CoV-2 virus pandemic through approved mRNA vaccines and therapeutic antibodies. M&A activity picked up substantially in H2 2020, further driving solid performance as the year came to a close. The fourth quarter alone drove a portfolio gain of 20.6% in CHF, 20.4% in EUR and 25.5% in USD for BB Biotech - reflecting a net gain of CHF 665 mn. In parallel, the share price appreciated by 10.9% in CHF and 9.0% in EUR. BB Biotech exited four holdings and added three new holdings in th
Generation Bio Announces Pricing of Public Offering
January 06, 2021 21:24 ET | Source: Generation Bio Co. Generation Bio Co. Cambridge, Massachusetts, UNITED STATES
CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the pricing of a public offering of 8,000,000 shares of its common stock at a public offering price of $24.50 per share. In addition, Generation Bio has granted the underwriters a 30-day option to purchase up to 1,200,000 additional shares of common stock at the public offering price, less the underwriting discount and commissions. All of the shares are being offered by Generation Bio.
Dec 14, 2020 5:28am Questions about how long gene therapies can exert their effects in the body have encouraged several companies to find new ways to make the treatments more durable. (Photo by kirstypargeter/iStock/Getty Images Plus/Getty Images)
When gene therapy developer Generation Bio raised $110 million in venture funding in January and then followed up six months later with a $230 million initial public offering, it was as sure a sign as any that investors are stoked about the next generation of gene therapies to treat rare diseases.
Their enthusiasm hasn’t waned during the year, either, despite challenges ranging from the COVID-19 pandemic delaying clinical trials to regulators pushing back some development timelines so they can gather more data on emerging gene therapies.
vimarsana © 2020. All Rights Reserved.